Compounds > isoproterenol

isoproterenol and roflumilast

isoproterenol has been researched along with roflumilast in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Huang, L; Jiang, HL; Lai, KF; Li, XS; Luo, ZH; Shan, WJ; Zhou, Q1
Huang, L; Lai, K; Li, X; Liu, A; Luo, Z; Mao, F; Shan, W; Wang, Z; Xie, J1
Huang, L; Lai, K; Li, X; Shan, W; Xie, J; Zhou, Q1
Freire, J; Qian, X; Tarran, R; Tyrrell, J1
Ansari, MN; Rehman, NU; Samad, A1
Abdel-Hakeem, EA; Fawzy, MA; Fouli Gaber Ibrahim, M; Refaie, MMM; Shaaban Mahmoud Abd El Rahman, E; Shehata, S; Zenhom, NM1

Other Studies

6 other study(ies) available for isoproterenol and roflumilast

ArticleYear
Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.
    Bioorganic & medicinal chemistry letters, 2012, Feb-15, Volume: 22, Issue:4

    Topics: Adrenergic beta-2 Receptor Agonists; Animals; Asthma; Drug Design; Guinea Pigs; Inhibitory Concentration 50; Molecular Structure; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Trachea

2012
Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD.
    Bioorganic & medicinal chemistry letters, 2013, Mar-01, Volume: 23, Issue:5

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate

2013
Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors.
    Bioorganic & medicinal chemistry letters, 2014, Jan-01, Volume: 24, Issue:1

    Topics: Adrenergic beta-2 Receptor Agonists; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Drug Design; Ethanolamines; Formoterol Fumarate; Humans; Molecular Structure; Phosphodiesterase 4 Inhibitors; Phthalazines; Receptors, Adrenergic, beta-2; Recombinant Proteins; Structure-Activity Relationship

2014
Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure.
    American journal of physiology. Lung cellular and molecular physiology, 2015, May-15, Volume: 308, Issue:10

    Topics: Adenosine; Adrenergic beta-Agonists; Aminopyridines; Analgesics; Benzamides; Bronchi; Cyclic AMP; Cyclopropanes; HEK293 Cells; Humans; Isoproterenol; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Mucosa; Smoking

2015
In Silico, Ex Vivo and In Vivo Studies of Roflumilast as a Potential Antidiarrheal and Antispasmodic agent: Inhibition of the PDE-4 Enzyme and Voltage-gated Ca++ ion Channels.
    Molecules (Basel, Switzerland), 2020, Feb-24, Volume: 25, Issue:4

    Topics: Aminopyridines; Animals; Antidiarrheals; Benzamides; Binding Sites; Calcium Channel Blockers; Carbachol; Castor Oil; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Diarrhea; Isoproterenol; Jejunum; Mice; Molecular Docking Simulation; Papaverine; Parasympatholytics; Phosphodiesterase 4 Inhibitors; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Rabbits; Verapamil

2020
Molecular mechanisms mediate roflumilast protective effect against isoprenaline-induced myocardial injury.
    Immunopharmacology and immunotoxicology, 2023, Volume: 45, Issue:6

    Topics: Animals; Antioxidants; Heart Injuries; Isoproterenol; Myocardium; Oxidative Stress; Rats; Rats, Wistar; Sirtuin 1; Vascular Endothelial Growth Factor A

2023